CorMedix (CRMD) Receivables - Other (2010 - 2025)

CorMedix's (CRMD) quarterly Receivables - Other came in at $4.0 million in Q3 2025, up 700.0% quarter-over-quarter from $500000.0 in Q2 2024.

CorMedix (CRMD) Receivables - Other (2010 - 2025) Analysis & Trends

CorMedix has disclosed Receivables - Other across 4 years of filings, most recently posting $4.0 million for Q3 2025.

Receivables - Other for Q3 2025 came in at $4.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $4.0 million (changed N/A YoY), and the FY2011 annual result was $493855.0, up 75.8% from the prior year.
Receivables - Other came in at $4.0 million for Q3 2025 at CorMedix, up from $500000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $4.0 million in Q3 2025 to a low of $500000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	CorMedix	631,378.03	-154.57 Mn	107.31 Mn

Download Data